Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Dysbiosis of the Gut Microbiota01:18

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Palladium-Catalyzed Cascade Annulation/Allylation of Alkynyl Oxime Ethers with Allyl Halides: Rapid Access to Fully Substituted Isoxazoles.

The Journal of organic chemistry·2019
Same author

Identification of crucial genes based on expression profiles of hepatocellular carcinomas by bioinformatics analysis.

PeerJ·2019
Same author

Three novel trehalase genes from <i>Harmonia axyridis</i> (Coleoptera: Coccinellidae): cloning and regulation in response to rapid cold and re-warming.

3 Biotech·2019
Same author

A new approach of electrochemical etching fabrication based on drop-off-delay control.

The Review of scientific instruments·2019
Same author

Correction: An organic-base catalyzed asymmetric 1,4-addition of tritylthiol to in situ generated aza-o-quinone methides at the H<sub>2</sub>O/DCM interface.

Chemical communications (Cambridge, England)·2019
Same author

Simple Is Best: A <i>p</i>-Phenylene Bridging Methoxydiphenylamine-Substituted Carbazole Hole Transporter for High-Performance Perovskite Solar Cells.

ACS applied materials & interfaces·2019

Related Experiment Video

Updated: Jun 4, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Engineered probiotics constitutively expressing SOD alleviate inflammatory bowel disease by targeting ROS.

Wenying Zhao1, Yusufu Rukeya1,2, Weiwen Bao1

  • 1Department of Laboratory Medicine, College of Health Science and Technology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Iscience
|June 3, 2026
PubMed
Summary

Engineered probiotic bacteria, KI@lSodA, reduce gut inflammation by restoring microbial balance and antioxidant defenses. This approach shows promise for treating inflammatory bowel disease (IBD) by targeting oxidative stress.

Keywords:
applied microbiologybiological sciencesmicrobiology

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jun 4, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Reactive oxygen species (ROS) drive gut microbiota dysbiosis, a key factor in intestinal inflammation.
  • Inflammatory bowel disease (IBD) patients show increased oxidative stress and reduced superoxide dismutase (SOD2) expression.
  • Oxidative stress and gut dysbiosis are critical in IBD pathogenesis.

Purpose of the Study:

  • To engineer a probiotic strain for treating intestinal inflammation by addressing oxidative stress.
  • To evaluate the therapeutic potential of KI@lSodA in preclinical models of enteritis.
  • To investigate the mechanisms by which KI@lSodA modulates gut health and immune responses.

Main Methods:

  • Engineered *Lactococcus lactis* (KI@lSodA) to express superoxide dismutase (SodA).
  • Administered KI@lSodA orally to murine models of DSS-induced enteritis (acute and chronic).
  • Assessed intestinal inflammation, epithelial barrier integrity, gut microbiota composition, and immune cell infiltration.

Main Results:

  • KI@lSodA significantly reduced intestinal inflammation and repaired epithelial damage in murine models.
  • Oral administration of KI@lSodA restored gut microbial homeostasis, increasing beneficial bacteria.
  • The probiotic suppressed phagocyte infiltration and modulated innate and adaptive immune responses.

Conclusions:

  • Engineered *Lactococcus lactis* (KI@lSodA) effectively attenuates intestinal inflammation.
  • This probiotic strategy restores redox balance and gut microbiota health, offering a novel therapeutic avenue for IBD.
  • Targeting oxidative stress via engineered probiotics presents a promising approach for IBD treatment and prevention.